RxDoctor Payments Data

Reyna Swift

Dermatology · Salem, ORNPI 1861812927

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.6% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 37.7% of the total.

$5,331in general payments, 2019–2025

Across 314 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$757
  • E.r. Squibb & Sons, L.L.C.$498
  • Pfizer$382
  • Lilly USA, LLC$340
  • Sun Pharmaceutical Industries Inc.$244
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,93993%
  • Education$3927%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,331 in reported general payments places this provider in the 75th percentile of 175 dermatology providers in Oregon.

See all dermatology providers in Oregon

Medicare billing

Part B allowed, 2024
$318,470
Medicare patients
774
Services billed
7,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$193,686
Dupixent PenDupilumab16$87,316
Taltz AutoinjectorIxekizumab12$80,938
OtezlaApremilast12$57,414
Clobetasol Propionate344$12,332
Tacrolimus57$7,023
Triamcinolone Acetonide263$3,592
Fluorouracil51$3,262
Metronidazole49$3,010
Ketoconazole174$2,603
Fluocinonide44$2,093
Doxycycline Hyclate105$2,077
Calcipotriene17$1,799
Doxycycline Monohydrate13$1,465
ValacyclovirValacyclovir Hcl44$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$757$193,68611 claims
AmgenOtezla$74$57,41412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 dermatology providers in Oregon.

Other dermatology in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →